Taysha Gene Therapies’ $181 Million IPO

Goodwin Procter LLP advised Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies on the deal.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, announced that the underwriters of its previously announced initial public offering have exercised their option to purchase additional shares of common stock at the public offering price of $20.00 per share, for total offering gross proceeds of approximately $181.0 million, before underwriting discounts and commissions and other offering expenses payable by Taysha.

Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies acted as joint book-running managers for the offering. Chardan acted as lead manager for the offering.

The Goodwin team was led by Robert Puopolo (Picture), Seo Salimi, Marishka DeToy, Tom Schaad, and Patty Shields, and included Julie Tibbets, Alex Varond, Sarah Wicks, Duncan Greenhalgh, Olivia Uitto, Roger Cohen, Madison Marcus, Andrew Hess, Sarah Bock, Leslie Nash, Janet Andolina, Matt Dunay, and Peter LaVigne.

Involved fees earner: Janet Andolina – Goodwin Procter; Sarah Bock – Goodwin Procter; Roger Cohen – Goodwin Procter; Marishka DeToy – Goodwin Procter; Matthew Dunay – Goodwin Procter; Duncan Greenhalgh – Goodwin Procter; Andrew Hess – Goodwin Procter; Peter LaVigne – Goodwin Procter; Madison Marcus – Goodwin Procter; Robert Puopolo – Goodwin Procter; Seo Salimi – Goodwin Procter; Tom Schaad – Goodwin Procter; Patty Shields – Goodwin Procter; Julie Tibbets – Goodwin Procter; Olivia Uitto – Goodwin Procter; Alexander Varond – Goodwin Procter; Sarah Wicks – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Goldman Sachs & Co.; Jefferies; Morgan Stanley;

Author: Ambrogio Visconti